Nonalcoholic fatty liver disease and psoriasis: What a dermatologist needs to know

Journal of Clinical and Aesthetic Dermatology

Volumn 8, Issue 3, 2015, Pages 43-45

  Prussick, Ronald ^a,b   Prussick, Lisa ^a,c   Nussbaum, Dillon ^a  

^a Washington Hospital Center   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA TOCOPHEROL; BIOLOGICAL PRODUCT; CYCLOSPORIN; ETANERCEPT; ETRETIN; METHOTREXATE; OMEGA 3 FATTY ACID; PSORALEN; SATURATED FATTY ACID;

AUTOIMMUNE DISEASE; COFFEE; DIET THERAPY; HUMAN; LIFESTYLE MODIFICATION; NONALCOHOLIC FATTY LIVER; PSORIASIS; REVIEW; ULTRAVIOLET A RADIATION; VITAMIN SUPPLEMENTATION;

EID: 84924764625     PISSN: 19412789     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Ailment Pharmacol Ther. 2011;33(5):525-540.
2. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28:155-161.
3. Van der Voort EAM, Koehler EM, Dowlatshahi EA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population based study. J Amer Acad Dermatol. 2014;70:517-524.
4. Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43:617-649.
5. Smith BW, Adams LA. Non-alcoholic fatty liver disease. Crit Rev Clin Lab Sci. 2011;48(3):97-113.
6. Miele L, Vallone S, Cefalo C, et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:778-786.
7. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:758-764.
8. Madanagobalane S, Anandan S. The increased prevalence of non-alcoholic fatty liver disease in psoriatic patients: a study from South India. Australas J Dermatol. 2012;53(3):190-197.
9. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut. 2007;56:1760-1769.
10. Campanati A, Ganzetti G, DiSario A, et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome and psoriasis. J Gastroenterol. 2013;48(7):839-846.
11. Gutierrez-Grobe Y, Chavez-Tapia N, Sanchez-Valle V, et al. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Ann Hepatol. 2012;11:350-355.
12. Eliades M, Spyrou E, Agrawal N, et al. Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2013;38:246-254.
13. Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr. 2013;33:231-248.
14. Vilarrasa E, Puig L, Alomar A. Biologic treatments for psoriasis in patients with hepatitis C virus infection and other liver diseases: experience in 29 patients. JEADV. 2010;24:P013.
15. Schramm C, Schneider A, Marx A, et al. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol. 2008;46:1369-1371.
16. th ed. Newtown, PA: Handbooks in Healthcare; 2011:50-59.
17. Taylor WJ, Korendowych E, Nash P, et al. Drug use and toxicity in psoriatic disease: focus on methotrexate. J Rheumatol. 2008;35:1454-1457.
18. Mirrakhimov AE, Polotsky VY. Obstructive sleep apnea and nonalcoholic fatty liver disease. Front Neurol. 2012;3:149-190.